In vitro models based on primary human hepatocytes (PHH) have been advanced for clearance (CL) prediction of metabolically stable compounds, representing state-of-the-art assay systems for drug discovery and development. Yet, limited cell availability and large interindividual variability of metabolic profiles remain shortcomings of PHH. Upcyte human hepatocytes (UHH) represent a novel hepatic cell system derived from PHH, exhibiting proliferative capacity for approximately 35 population doublings. UHH from three donors were evaluated during culture for up to 18 days, investigating relative mRNA expression and in situ enzyme activity of cytochrome P450s (P450s), UDP-glucuronosyltransferases, and sulfotransferases. Furthermore, UHH were used for predicting hepatic CL of 21 marketed low to intermediate CL drugs. In a typical experiment, expansion from 3.9 3 10 6 up to 8.5 3 10 7 cells was achieved during subculture.
Introduction
Renal and hepatic clearance (CL) predominantly determines total CL, an essential parameter describing the pharmacokinetic (PK) profile of new chemical entities. An estimated 60% of marketed drugs are cleared by hepatic cytochrome P450-mediated metabolism (McGinnity et al., 2004) . Hence, various methodologies based on in vitro data have been reported for the prediction of metabolic CL (Ring et al., 2011) , routinely assessed early during drug discovery. Primary hepatocyte suspensions are commonly preferred for the in vitro determination of intrinsic CL (CL int ) , representing a fully competent metabolic model (Blanchard et al., 2006; Hewitt et al., 2007) with an expression pattern of drug-metabolizing enzymes (DMEs) comparable to the liver of origin (Richert et al., 2006) . However, suspended hepatocytes lose viability and metabolic activity within a few hours (Skett, 1994; Gebhardt et al., 2003) , which frequently averts reliable and accurate CL int determination, in particular for slowly cleared compounds (Di and Obach, 2015; Hutzler, et al., 2015) .
As low hepatic CL generally is requisite for improving bioavailability and duration of action of new chemical entities, high throughput optimization strategies were implemented in drug discovery, leading to an increase in metabolically stable compounds over the past years (Di et al., 2013) . Consequently, a number of methodologies have been developed enabling longer incubation periods and thus sufficient metabolic turnover. For example, the hepatocyte relay method (Di et al., 2012) showed successful CL int predictions for low and intermediate CL drugs by sequential short incubations in suspended hepatocytes. Several reports suggest plated hepatocytes to have advantages over suspensions for CL int determinations of low turnover compounds (Blanchard et al., 2004; Treijtel et al., 2004; Griffin and Houston, 2005; Smith et al., 2012) . However, deregulation of gene expression of DMEs after plating is a major drawback of primary hepatic cell cultures (Richert et al., 2006) , thus complicating the development of reliable long-term culture models. The twodimensional sandwich or hepatic cocultures partially overcome these obstacles showing prolonged longevity, preserved hepatocyte-specific functions, as well as lower, yet longer sustained metabolic capabilities (LeCluyse et al., 1996; Guguen-Guillouzo and Guillouzo, 2010) . More recently, microfluidic (Novik et al., 2010) and static micropatterned hepatocyte coculture models (Khetani and Bhatia, 2008) have been described as advanced tools for long-term applications (Wang et al., 2010) and shown to be suitable for CL prediction . These reports have been complemented by comprehensive studies on metabolism and disposition of slowly metabolized drugs (Ramsden et al., 2014a (Ramsden et al., , 2014b .
Despite these promising developments, all primary human hepatocyte (PHH) systems, regardless of the culture conditions applied, are limited by availability, high phenotypical variability, and low batch-tobatch consistency (Donato et al., 2013) . This affects the outcome of in vitro assays and impedes reliable extrapolation and prediction of human CL (Gómez-Lechón et al., 2004) . For example, in vitro metabolic CL of 14 drugs varied by three-to fivefold among 10 individual donors (Shibata et al., 2002) . Alternative hepatic cell systems have been intensively evaluated as potential surrogate; however, hepatoma and engineered liver-derived cell lines often show poor expression of relevant DMEs or unbalanced drug-metabolizing properties after transfection (Andersson et al., 2012; Gómez-Lechón et al., 2014) .
Second-generation upcyte human hepatocytes (UHH) are derived from PHH by a recently reported mechanism, including lentiviral transduction of human papilloma virus genes (E6, E7) and oncostatin M-dependent stimulation of proliferation (Levy et. al, 2015) . UHH thereby inherit an extended, but mortal life span while lacking expression of fetal markers a-fetoprotein and CYP3A7 (Levy et. al, 2015) . In contrast, expression of adult hepatic markers (albumin and cytokeratin 8 and 18) and mature hepatic functions, such as storage of glycogen; urea production; basal phase II and P450 activity; responsiveness to prototypical inducers of CYP1A2, CYP3A4, and CYP2B6; as well as functional polarization were reported for differentiated UHH (Burkard et al., 2012; Levy et al., 2015) .
The objective of the present study is to investigate the expression and activity of important DMEs in cultured UHH and to evaluate the impact of culture conditions and cultivation time, and finally, suitability for hepatic CL prediction using up to 21 marketed medium and low turnover drugs. To our knowledge, this is the first report describing the metabolic competence of long-term sandwich-cultured UHH and assessing the applicability for human CL prediction of slowly metabolized compounds.
Materials and Methods
Chemicals and Reagents. The 1-hydroxymidazolam, 1-hydroxymidazolamd 4 solution, (2S, 3S)-hydroxybupropion, 4-hydroxydiclofenac, 4-hydroxymephenytoin, 6b-hydroxytestosterone, 6b-hydroxytestosterone-d 3 solution, 7-hydroxycoumarin, 7-hydroxycoumarin glucuronide, 7-hydroxycoumarin sulfate, acetaminophen, acetaminophen-d 4 solution, alprazolam solution, amodiaquine dihydrochloride dihydrate, atomoxetine hydrochloride solution, bupropion hydrochloride, dextromethrophan hydrobromide, dexamethasone, dextrorphan, dextrorphan-d 3 solution, diazepam, diclofenac, dimethylsulfoxide, b-estradiol, flecainide, glimepiride, imipramine hydrochloride, lidocaine, metoprolol tartrate, N-desethyl amodiaquine-d 6 dihydrochloride solution, omeprazole, ondansetron, oxazepam solution, penicillin-streptomycin (100Â), phenacetin, prednisolone, rifampicin, riluzole, risperidone, S-mephenytoin, testosterone, theophylline, tolbutamide, trypan blue solution, voriconazole, warfarin, and Williams´Medium E were purchased from Sigma-Aldrich (St. Louis, MO). HEPES buffer (1 M, pH 7.4) , fetal bovine serum, Dulbecco's phosphate-buffered saline (Dulbecco's PBS) with and without calcium or magnesium, and stabilized L-glutamine (Glutamax, 100Â) were from Life Technologies (Darmstadt, Germany); insulin-transferrin-selenous acid and bovine serum albumin pre-mix (100Â) and Matrigel phenol red-free were from Corning/BD Biosciences (Bedford, MA); and trypsin/ETDA (0.5/0.2%) was from PAN Biotech (Aidenbach, Germany). Atazanavir was purchased from Biotrend (Cologne, Germany); b-estradiol-3bD-glucurodide from Santa Cruz (Dallas, TX); a-naphthyl-b-D-glucuronide from Sequoia Research Products (Pangbourne, UK); 4-hydroxymephenytoin-d 3 was from TRC (Toronto, Canada); hydroxybupropion-d 8 and ( 13 C 6 ) 49-hydroxydiclofenac were from Syncom (Groningen, The Netherlands); Midazolam (Dormicum i.v.) was from Roche (Basel, Switzerland); and meloxicam was from internal source (Boehringer Ingelheim, Biberach, Germany). Hepatocyte thawing medium, hepatocyte preculture medium (PCM), hepatocyte metabolism conditioning medium (MCM), and hepatocyte high performance medium together with reagents A, B, and C were purchased from Medicyte (Heidelberg, Germany).
In Vitro Culture of Upcyte Hepatocytes. Cryopreserved UHH from female Caucasian donors (151-03, 653-03, 10-03) were purchased from Medicyte and thawed according to the vendor's protocol. Briefly, after rapid thawing at 37°C, cells were suspended in 50 mL hepatocyte thawing medium, separated by centrifugation at 90g for 5 minutes at room temperature, and seeded at a density of 5000-6000 cells/cm 2 in PCM supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine, and the reagents A, B, and C (as part of proprietary culture medium), onto collagen I-coated T-150 flasks (Corning/BD Biosciences). Cell viability and cell number were determined by trypan blue exclusion. UHH were cultured for 5 days (95% humidity, 37°C, and 5% CO 2 ) with change of culture medium every other day. Cultures were split at day 5 after seeding and maintained for additional 48 hours. In brief, cells were washed with Dulbecco's PBS without calcium or magnesium, secondly with trypsin/EDTA (0.05%/0.02%) solution, followed by incubation with trypsin/EDTA (0.05%/0.02%) solution for 3-4 minutes at 37°C in humidified atmosphere. Detached cells were suspended in PCM supplemented by 10% fetal calf serum and centrifuged at 90g for 5 minutes at room temperature. The remaining cell pellet was resuspended in fresh PCM, and the cell number was adjusted to achieve a seeding density of 5000-6000 viable cells/cm 2 . Cultures of UHH were trypsinized after 7 days in expansion culture and seeded onto collagen I-coated 24-well plates (Corning/BD Biosciences) at high cell density (150,000 cells/cm 2 ), according to the protocol mentioned above. Cells were incubated at 95% humidity, 37°C, and 5% CO 2 . After cell attachment, PCM together with nonadherent UHH was discarded. Cells were washed once with ice-cold Dulbecco's PBS; overlaid with ice-cold 0.25 mg/mL Matrigel in MCM (0.5 mL/well); supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine, and reagents A and C (as part of the proprietary culture medium); and incubated for 24 hours at 37°C, 5% CO 2 , and 95% humidity to obtain the sandwich cultures (SC). For single monolayer cultures (MC), fresh MCM without Matrigel was added. UHH in MC or SC were kept for up to 18 days in 24-well format with fresh medium (0.7 mL/well) replaced daily prior to determination of in situ enzyme activity and isolation of RNA. Morphology of cultures was assessed daily by light microscopy (Eclipse TS100 inverted microscope; Nikon, Düsseldorf, Germany) to ensure integrity and confluence of cell monolayer adequate for experiments.
In Vitro Culture of Primary Human Hepatocytes. Cryopreserved PHH from four male (Hu1601, Hu8163, HC5-27, CDP) and six female (371, 303, 271, YJM) Caucasian donors (Supplemental Table 1 ) were purchased from Life Technologies (Darmstadt, Germany), Corning/BD Gentest, TebuBio (Offenbach, Germany), and BioreclamationIVT (Frankfurt/Main, Germany). The cells were thawed and plated onto collagen I-coated 24-well plates (Corning/BD Biosciences; APSciences, Columbia, MD) at cell densities, according to the vendor's recommendation and following the corresponding protocols (Supplemental Table 1 ). Attached PHH were overlaid with 0.25 mg/mL Matrigel in culture medium typically 4-6 hours after plating and maintained under daily change of medium for up to 10 days at 95% humidity, 37°C, and 5% CO 2. In situ enzyme activity of UGT, sulfotransferase (SULT), as well as of CYP1A2, CYP3A4, CYP2B6, CYP2C9, CYP2C19, and CYP2D6 was measured at days 1, 3, 5, 7, and/or day 10. Cultures were checked daily by light microscopy for intact phenotypical morphology and confluence.
Assessment of In Situ Enzyme Activity. UGT, SULT, and P450 isoformspecific metabolite formation rates were determined in situ at days 1, 3, 5, 7, 10, 14 , and/or 18 after plating to 24-well plates using different batches of UHH. Cells were washed once with Dulbecco's PBS and Williams´Medium E (0.5 mL/well) supplemented with 6.25 mg/mL insulin, 6.25 mg/mL transferrin, 6.25 ng/mL selenous acid, 5.35 mg/mL linoleic acid, 1.25 mg/mL bovine serum albumin, 0.1 mM dexamethasone, 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mM L-glutamine containing isoform-specific probe substrates added. Metabolite formation (Supplemental Table 2 ) was monitored over time (0-45 or 0-90 minutes) via liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) quantitation. The activity of each enzyme was assessed by separate probe reactions. Within each experiment, incubations were performed in three (n = 3) or two (n = 2) replicates per substrate. Incubation samples of 25 mL per time point were diluted in 475 mL ice-cold aqueous quench solution containing 5% acetonitrile, 5% methanol, 0.1% formic acid, and the respective stable isotope-labeled metabolite as internal standard (ISTD). A sample volume of 5 mL was analyzed by LC-MS/MS (Supplemental Table 3 ) operated with an atmospheric pressure electrospray ionization source, composed of a HTS PAL autosampler (CTC Analytics, Zwingen, Switzerland), a 1100 series binary pump and degasser (Agilent Technologies, Santa Clara, CA), and API 4000 QTRAP (AB Sciex, Foster City, CA). High performance liquid chromatography was performed on a YMC-Triart C18, 30 Â 2.0-mm, 3-mm column (YMC Europe, Dinslaken, Germany) and a X-Terra MS C18, 50 Â 2.1-mm, 5-mm column (Waters, Eschborn, Germany). The mobile phase consisted of 0.1% (v/v) formic acid in water (A) and 0.1% (v/v) formic acid in 47.5/47.5/5% (v/v) methanol/ acetonitrile/water (B) or 5 mM ammonium formiate pH 3.5 (A) and 89.95/10/ 0.05% (v/v) acetonitrile/methanol/formic acid (B) for gradient elution of 6b-OHtestosterone.
Gene Expression Analysis. Total RNA was isolated subsequent to in situ enzyme activity measurements using the RNeasy Mini Kit (Qiagen, Hilden, Germany) together with the Qiagen Qiashredder for homogenization and oncolumn DNA digestion (RNase-free DNase Set) from the same supplier. Four wells of cultured cells were pooled and used as representative sample for each assay time point and culture format. Purified RNA was quantified spectrophotometrically at l = 260 (NanoDrop 1000 spectrophotometer; Thermo Fisher Scientific, Schwerte, Germany). Purity and integrity of RNA were assessed by capillary electrophoresis column using RNA 6000 LabChips and Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). A quantity amounting to 400 ng total RNA per sample was reverse transcribed for first-strand cDNA synthesis following the protocol for High Capacity cDNA RT Kit (Applied Biosystems, Foster City, CA). Relative mRNA expression of main P450s were analyzed by quantitative real-time PCR, as published previously (Schaefer et al., 2012) , using custom-made primers (Biomers GmbH, Ulm, Germany) and inventoried TaqMan gene expression assays (Life Technologies/AB).
Analysis and Normalization of Gene Expression Data. Threshold cycle values were determined using the 7500 Fast software v2.06 (Applied Biosystems, Darmstadt, Germany). The housekeeping gene b-actin was applied as endogenous control for normalization of gene expression data, quantified in the same sample (duplexed reverse-transcription polymerase chain reaction) for custom-made assays or as separate sample on the same assay plate for inventoried assays. In each real-time PCR run relative expression levels were calculated based on the comparative threshold cycle method (Schmittgen and Livak, 2008) , correcting for actual PCR efficiencies for each target and the reference gene (Richert et al., 2009) in each real-time PCR run.
In Vitro Substrate Depletion Assay. Loss of parent compound and subsequent in vitro CL int was determined at designated time points (days 5, 7, 10, and 14) in confluent UHH cultures in MC or SC configuration (24-well format). Incubations were performed in high performance medium (0.75 mL/ well), supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine, and reagent A (as part of proprietary culture medium) containing the test compound at a final concentration of 1 mM. Maximum solvent concentration in culture medium was 0.1% dimethylsulfoxide (DMSO), except for oxazepam, atomoxetine, and alprazolam (0.1% DMSO/0.05% methanol). Each compound was tested in three replicates (n = 3; three separate wells per compound), unless otherwise stated, over a maximum incubation period of 120 hours. A volume of 25 mL was removed from the supernatant at various time points and added to 475 mL ice-cold quench solution [acetonitrile/methanol/water 5/5/95% (v/v) and 0.1% formic acid] containing 25 nM BI 1052 as ISTD provided in 96-deep-well plates. Incubations on the same plate without cells served as control for any unspecific loss of parent compound. For determination of remaining parent compound, 5 mL each sample was subjected to LC-MS/MS investigation, as described above, using multiple reaction monitoring. The mass spectrometry parameters for each analyte (Supplemental Table 4 ) were individually optimized by using the Automaton software (Applied Biosystems/MDS Sciex) and/or manual tuning. Chromatographic separations were performed on YMC-Triart C18, 30 Â 2.0-mm, 3-mm (YMC Europe, Dinslaken, Germany) column at a flow rate of 400 mL/min or 500 mL/min (for diclofenac). The mobile phase consisted of 0.1% (v/v) formic acid in water (A) and 0.1% (v/v) formic acid in 47.5/47.5/5% (v/v) methanol/acetonitrile/water (B) .
Data Analysis and Prediction of Hepatic CL. To determine first-order rate constant k and subsequently the in vitro half-life time (T 1/2 ), the drug substrate/ ISTD peak area ratio of each given time point was analyzed relative to the peak area ratio of the starting condition T 0 , calculating the percentage of parent compound remaining. The log-transformed data were plotted versus incubation time, and the absolute value of the slope obtained by linear regression analysis was used to estimate in vitro T 1/2 of each compound (eq. 1):
In vitro CL int was then estimated from in vitro T 1/2 determined by eq. 1 and scaled to whole liver (in units of mL/min/kg) using a hepatocellularity of 120 Â 10 6 cells g 21 liver For the succeeding comparison of in vitro and in vivo metabolism on the level of hepatic CL, the in vitro CL int was modeled (eq. 3), according to the well-stirred liver model (Houston, 1994) either with or without correction for fraction unbound in plasma (f u ) and in respect to an average liver blood flow (Q H ) of 20.7 mL min 21 kg 21 (Davies and Morris, 1993) :
Comparison with In Vivo Hepatic CL Data. In vitro predicted hepatic CL data were compared with human in vivo hepatic CL (CL H ) values calculated by using eq. 4 in consideration of published pharmacokinetic parameters (Supplemental Table 5 ) and the assumption that systemic blood CL corrected to nonrenal CL values equals CL H .
Total plasma CL data (CL total ) were compiled from various scientific references describing studies with i.v. dosing, unlike otherwise indicated. In the case in which only CL values after oral administration were available, the systemic CL was estimated from CL/F, according to eq. 5.
For reference drugs undergoing metabolic degradation via genetic polymorphic P450 enzymes, thus showing different pharmacokinetic profiles, only PK parameters reported for extensive metabolizers were taken into account. In case of missing normalization to body weight for a reported in vivo CL value, the published mean body weight or a standard body mass of 70 kg for humans was used for calculation. If the blood-to-plasma ratio value was not available, it was assumed as 1. Analysis of Prediction Accuracy and Precision. Prediction accuracy for each reference drug was assessed by calculating the prediction error, defined as ratio of in vitro predicted CL H and in vivo nonrenal CL from literature (eq. 6). The average fold error (AFE; eq. 7), the absolute average fold error (AAFE; eq. 8), and the root mean squared error (RMSE; eq. 9) were estimated as measures of bias, accuracy, and precision, respectively (Ito and Houston, 2004; Tang et al., 2007) , for each set of predictions.
Fold 2 error ¼ CL predicted CL observed ð6Þ
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Results Culture Characteristics and Morphology of Plated Upcyte Hepatocytes. All batches of UHH obtained from three donors were used within a population-doubling range of 25-30. Cell viability and yield after thawing and expansion were highly consistent across studies (Supplemental Table 6 ). Typically, 3-5 Â 10 6 viable cells were recovered and expanded within the subculture period to a maximum of 8.5 Â 10 7 cells. Cell yields of donor 10-03 were significantly reduced (2.4 Â 10 7 cells), essentially due to an increased collagen formation (communicated by the vendor), thus impeding subcultivation and passaging. UHH from all tested donors shared a common morphologic phenotype, as described by Burkard et al. (2012) , clearly distinguishable from plated PHH (Supplemental Fig. 1 ). After attachment, UHH showed an undifferentiated and partly elongated morphology. Along with proliferation and increasing confluence, cells formed clusters exhibiting a more hepatocyte-like morphology, that is, cubical shape, tight cell-cell contacts, one or two nuclei, intact plasma membranes, and bile canalicular-like structures, as seen for PHH cultures (Supplemental Fig. 2 ). By microscopic inspection, neither a significant perturbation of morphology nor loss of confluence was observed over 18 days in culture or during incubations without medium change for up to 120 hours.
Effect of Culture Condition on P450 mRNA Expression and Enzyme Activity. UHH from donor 151-03 were used to select optimal assay culture format and preculture time. Assessment was based essentially on the in situ enzyme activities of CYP3A4, CYP2C9, CYP2C19, and CYP2D6 and supported by mRNA expression analysis. Differences in enzyme activity levels between sandwich-cultured (SC) UHH and monolayer cultures (MC) manifested over culture time (Supplemental Fig. 3 ), resulting in significantly elevated P450 enzyme activity levels in SC, as illustrated for day 7 (Fig. 1A) . P450 activities were found 1.5-fold (CYP3A4), 1.8-fold (CYP2C9), 2.0-fold (CYP2C19), and 1.8-fold (CYP2D6) higher in SC. However, no significant increase in enzyme activity was observed for UGT and SULT (data not shown). A similar pattern was seen for P450 mRNA expression. Overall higher P450 expression levels were consistently measured in SC compared with MC (Fig. 1A ). For example, relative mRNA levels of CYP3A4 and CYP2C19 were found 2.6-and 2.4-fold higher in SC format, respectively. Consequently, all subsequent studies with UHH were performed in sandwich configuration.
Effect of Culture Time on mRNA Expression and Enzymatic Activity of P450, UGT, and SULT. We examined expression of major P450s, UGT, and SULT for up to day 18, focusing on in situ enzyme activity measurements as a functional readout. mRNA expression analysis was performed concomitantly at designated time points. For donor 151-03, mRNA transcripts of the major P450s were expressed over the observation period, revealing bell-shaped mRNA expression profiles, as shown for days 5-14 (Fig. 1B) , with maximum levels typically at day 7. A reduction in gene expression (.threefold relative to day 7) was seen at day 14 for CYP3A4 and CYP2D6, and to a lower extent (#threefold) for CYP1A2, CYP2B6, CYP2C9, and CYP2C19 (Supplemental Fig. 4 ). CYP2B6, CYP3A4, and CYP2C9 were the most abundant P450s quantified, whereas mRNA levels for CYP1A2 were found lowest (Fig. 1B) . Next, P450 mRNA expression was examined in two additional donors of UHH (653-03 and 10-03). Distinct quantitative differences were observed at day 7, in particular for CYP3A4 and CYP2C19, exhibiting significantly lower levels compared with donor 151-03 (Fig. 1C) . However, all donors showed a particularly high CYP2B6 and low CYP1A2 mRNA expression when measured relative to endogenous control b-actin. Remarkably, mRNA levels increased over time in cultures of donor 653-03 (Supplemental Table 7 ).
Corresponding in situ enzyme activities of most P450 isoforms, as well as of UGT and SULT, were constant or even increasing with time, as shown for CYP1A2, CYP3A4 CYP2C9, CYP2C19, CYP2D6, UGT, and SULT, determined for donor 151-03 (Fig. 2 , A-C; Supplemental Table 7 ) and donor 653-03 (Fig. 2 , D-F; (Supplemental Table 7 ). An exception was seen for CYP3A4 levels (donor 151-03), declining by 30-50% between day 5 and day 14 ( Fig. 2A) . Absolute metabolite formation rates were highest in UHH cultures of donor 151-03, when comparing activity levels at day 7 (Supplemental Table 7 ), consistent with the mRNA expression data (Fig. 1C) . For donor 10-03, CYP2C19 activity was found below lower limit of quantification (Supplemental Table 7 ), corresponding to the low mRNA expression (Fig. 1C ) and in line with the detected *2A/*2A polymorphism (data not shown), linked to a poor metabolizer phenotype (Chang et al., 2014) .
To further examine the effect of extracellular matrix protein, and to further evaluate appropriate preculture time, we determined metabolic turnover of selected marketed reference drugs at different time points in SC and MC by substrate depletion. In general, greater turnover rates were observed in SC (Supplemental Fig. 5 ), correlating well with the aforementioned results. The levels of turnover as well as predicted CL H for tolbutamide (CYP2C9) and oxazepam [uridine 59-diphosphoglucuronosyltransferase (UGT)] were not significantly different between days 7, 10, and 14 in SC using UHH of donor 151-03 (Supplemental Fig. 6A ), which is found in line with the constant activity levels observed (Fig. 2, A and C) . As expected from the CYP3A4 activity profile ( Fig. 2A) , turnover was lower for alprazolam at days 10 and 14 (Supplemental Fig. 6A ). Consequently, highest prediction accuracy was achieved based on CL int values determined at days 5 or 7, whereas predictions of day 14 resulted in .threefold underestimation (Supplemental Fig. 6C ). Based on these results, especially with regard to the decreasing CYP3A4 activity (151-03), a preculture time of 7 days in confluent SC was selected for subsequent analyses.
We next compared the absolute metabolite formation rates determined in situ from plated UHH averaged over the tested cultivation time with corresponding enzyme activity levels measured for sandwichcultured PHH from 10 different donors (data not shown). Formation rates for CYP1A2 and 2C9 were found to be lower; for 2B6 significantly higher in UHH; whereas enzyme activity levels for CYP3A4, 2C19, 2D6, and UGT were comparable (Fig. 3) , thereby supporting further investigation of UHH as in vitro system for examining metabolic turnover and predicting human CL. Applying the well-stirred model and considering plasma protein binding, CL H for none of the 19 compounds were predicted within twoor threefold of the observed in vivo CL nonrenal using UHH of donors 653-03 and 10-03 (Fig. 4 , B and C), and only 21% (4 of 19 compounds) were predicted within threefold error using UHH of donor 151-03 (Fig. 4A) . In contrast, prediction accuracy was significantly improved if plasma protein binding was not included in the estimations for in vivo CL H consistently for all donors (Fig. 4 D-I ). Good correlation between predicted CL H and observed in vivo CL values was observed for the subset of low CL drugs (Fig. 4, D-F) , in particular for donor 151-03 Fig. 2 . P450, UGT, and SULT enzyme activity over time in culture. Enzyme activities were determined by in situ metabolite formation of 6bOH-testosterone (3A4), 4OH-diclofenac (2C9), 4OH-mephenytoin (2C19), dextrorphan (2D6), acetaminophen (1A2), 7OH-coumarin glucuronide (UGT), and 7OH-coumarin sulfate (SULT) at distinct time points in sandwich cultures of UHH from donor 151-03 (A-C) and donor 653-03 (D-F). Values for each time point represent mean 6 S.D. of at least two and up to six individual experiments (n = 2-6), each with duplicate or triplicate determinations in separate wells of the culture plate (n = 2 or n = 3). Fig. 3 . Comparison of P450 and UGT metabolite formation rates between upcyte human hepatocytes and primary human hepatocytes. Correlation of absolute enzyme activity levels determined in sandwich-cultured UHH from donor 151-03 for CYP3A4, CYP2C9, CYP2C19, CYP2D6, CYP1A2, UGT (derived from five separate experiments; n = 5), and CYP2B6 (from three separate experiments; n = 3) with formation rates obtained from up to 10 different donors of plated PHH (Supplemental Table 1 ). Levels are expressed as mean 6 S.D. over the actual cultivation periods of day 5 to day 14 (UHH donor 151-03) and day 1 to day 10 (PHH). Fig. 4D) : CL H for 73% (8 of 11 compounds) were predicted within twofold of in vivo CL nonrenal , and within threefold of actual for 82% (9 of 11 compounds) with a trend for overpredicting the actual. The resulting AFE was 1.9, and the AAFE 2.0 (Table 1) . Prediction success rate was even 80% considering a twofold deviation, if theophylline is excluded. In contrast, twofold accuracy was only 36% (4 of 11 compounds) for donors 653-03 and 10-03. A clear trend toward a negative bias was observed for intermediate cleared drugs, consistently for the three donors (Fig. 4, G-I ) with an AFE of 0.3, 0.1, and 0.2 (Table 1) . For 2 of 8 compounds (25% accuracy) predictions fell within twofold, and for 5 of 8 compounds (63%) within threefold of in vivo CL nonrenal , respectively, using UHH donor 151-03. Within threefold accuracy was 0% for donor 10-01 and 25% for UHH 653-03 ( Table 1) .
As expected from the P450 activity profiles described above, generally greater consumption of parent drug was observed for donor 653-03 at days 10 and 14 in comparison with day 7 ( Supplemental  Fig. 6B ). Ultimately, overall prediction performance was improved by extending the preculture period to day 10 for this donor (Table 1) . Although a stronger overprediction was seen for CYP2C9 and CYP2C19 substrates, for example, tolbutamide and diazepam, accuracy of predicted CL H , especially for CYP1A2, CYP3A4, and CYP2D6 substrates, was higher (Supplemental Fig. 6D ). This bias seen for each single compound is reflected in the increased value of AFE in the overall evaluation (0.6 for day 10 compared with 0.4 for day 7). Finally, highest accuracy and precision for the prediction of human CL H were achieved with UHH from donor 151-03 (Table 1) . Over the full set of drugs tested, 53% (10 of 19 compounds) were correctly predicted within twofold and 74% within threefold to in vivo CL nonrenal , respectively.
Interassay Variability of Enzyme Activity and CL Prediction. Robustness of the UHH in vitro system was evaluated by examining additional batches of donor 151-03 for variability in DME activity and reproducibility of CL prediction. UGT, SULT, and P450 isoformspecific metabolite formation rates determined at day 7 in SC, prior to substrate depletion experiments, were highly reproducible in five Table 9 ): interassay variation (%CV) was found to be within 11-24% for all P450 enzymes, except for SULT and CYP2C9 with 33-39%. The robust enzyme activity levels correlated well with predicted CL H data obtained by separate experiments. Variation (%CV) between predicted in vivo CL H values for the 19 (n = 3) and 2 additional CYP1A2/CYP2D6 (n = 2) reference drugs (Table 2 ) was within 4-21% (based on mean 6 S.D. for each experiment) and with 28-35% slightly higher for CYP2C9 substrates tolbutamide, meloxicam, and warfarin. For metoprolol and flecainide, the %CV was exceptionally high (.40%). Highly consistent prediction fold errors were observed for the majority of reference compounds in three individual experiments (Table 2) , leading to a reproducible prediction accuracy of 73% for the slowly metabolized compounds being predicted within twofold of observed in vivo CL nonrenal .
Discussion
In recent years, considerable efforts were made to provide advanced hepatic in vitro systems mitigating the loss of DME activities to reliably predict human CL of metabolically stable compounds (Di and Obach, 2015; Hutzler et al., 2015) . However, limited availability and large variability in DME expression and activity remain shortcomings of PHH, in particular for routine screening applications in drug discovery. In contrast, the recently introduced upcyte human hepatocytes exhibit an extended proliferative aptitude (Burkard et al., 2012) .
In the present study, we evaluated second-generation UHH for their time-dependent metabolic capabilities, focusing on the enzymatic activity of the main and polymorphic P450s, and in a second step for predicting CL H of low-and intermediate-cleared drugs. Our approach was guided by considerations for a potential applicability of UHH in a drug discovery setting.
Downregulation of P450 transcripts contributes to the phenotypic instability reported for long-term cultures of PHH (Richert et al., 2006) . Hepatocyte-specific functions, including the expression of DMEs, can be preserved, at least to some extent, in a three-dimensional environment such as Matrigel sandwich systems (Dunn et al., 1991; LeCluyse, 2001) . We demonstrated that an overlay of extracellular matrix protein significantly increases both mRNA expression and activity of main P450s in sandwich-cultured UHH compared with monolayer cultures (Fig. 1) . Furthermore, expression and functionality were confirmed for major P450s as well as for UGT and SULT enzymes, revealing donor-specific expression and activity levels comparable to plated PHH. In contrast, human hepatic cell lines, for example, HepG2 or HuH7, lack relevant hepatocyte functions (Andersson et al., 2012) and often show strong divergence in DME expression compared with PHH (Guo et al., 2011) . The consistently high CYP2B6 The following drugs are excluded from statistical analysis due to lack of significant depletion of parent compound: # theophylline and † theophylline, flecainide, voriconazole, diazepam, warfarin, atazanavir, and metoprolol. Fig. 5 . Reproducibility of P450, UGT, and SULT enzyme activity, Enzyme activity levels of CYP3A4, CYP2C9, CYP2C19, CYP2D6, CYP1A2, UGT, and SULT were measured by in situ metabolite formation of 6bOH-testosterone (3A4), 4OH-diclofenac (2C9), 4OH-mephenytoin (2C19), dextrorphan (2D6), acetaminophen (1A2), 7OH-coumarin glucuronide (UGT), and 7OH-coumarin sulfate (SULT) in sandwich-cultured UHH of donor 151-03 at day 7. Data points represent individual metabolite formation rates from five individual experiments (n = 5), plotted together with the mean 6 S.D.
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at ASPET Journals on August 27, 2017 dmd.aspetjournals.org Downloaded from expression and activity seen for UHH in our studies may be attributed to dimethylsulfoxide in the proprietary culture medium, a known inducer of hepatocyte redifferentiation (Su and Waxman, 2004 ) and P450 expression (LeCluyse et al., 2000) . In contrast to the rapid decline in P450 activity observed for plated PHH (Smith et al., 2012) , UHH from two donors showed sustained enzymatic activity for UGT, SULT, and the majority of P450 isoforms over a period of up to 18 days, with maximum activity levels typically reached at day 7. Interestingly, functional activities were constantly increasing over 14 days for donor 653-03 (Fig. 2) , potentially indicating ongoing adaptation to the in vitro microenvironment, differentiation, and/or stabilization of phenotypic functions, including P450 expression, as described for HepaRG cells (Kanebratt and Andersson, 2008) . At large, the enzyme activity profiles monitored for P450s, UGT, and SULT under the applied conditions support the utility of UHH in drug metabolism studies over a culture period of at least day 5 to day 14 after seeding. It is nevertheless conceded that a more comprehensive characterization including non-P450 enzymes and transporters is needed to fully assess the potential of UHH as a general alternative to PHH. Consequently, the present investigations on CL were focused on marketed drugs with primarily P450/UGT-mediated hepatic elimination pathways.
Hepatic blood clearance values were scaled from in vitro CL int using the physiologically based in vitro-in vivo direct scaling approach and the well-stirred model, commonly accepted for low CL compounds (Lavé et al., 2009 ). Applying our assay conditions, CL H predictions yielded highest accuracy when plasma protein binding was not considered, with a tendency for overestimation in particular for low CL compounds (Fig. 4) . In contrast, considering the free drug concentration in plasma resulted in a marked underprediction of in vivo CL H . We acknowledge that our results appear counterintuitive to the free-fraction hypothesis, taking into account that no serum was added to the incubations. Accordingly, one would have expected similar results as reported by Chan et al. (2013) , who achieved highest prediction accuracy of in vivo CL H with long-term PHH cocultures (HepatoPac) under protein-free conditions, including correction for plasma protein binding. Furthermore, by addition of serum, other groups have demonstrated an increased prediction accuracy (Blanchard et al., 2006; Chao et al., 2009 ), assuming a protein-mediated drug uptake or an improved simulation of protein binding/uptake/ metabolism interplay (Hallifax and Houston, 2012; Poulin et al., 2012) . To explain the apparent discrepancy of our results, we considered an extensive human serum albumin (HSA) production by cultured UHH as possibility leading to an increased protein content in the incubation matrix, in addition to the Matrigel protein overlay (0.18 mg/mL) contributing to nonspecific binding, or even acting as an additional diffusion barrier (Treijtel et al., 2004) . However, secretion of HSA has recently been shown to be comparable between UHH and PHH (Levy et al., 2015) , thereby regarded as unlikely to account for the observed discrepancy. Furthermore, we could demonstrate that metabolic turnover of even highly protein-bound compounds was not reduced in sandwich-cultured UHH compared with MC ( Supplemental  Fig. 5 ). To this end, it may be disputed whether bovine serum albumin present in the proprietary culture medium (3.75 mg/mL) allows for negligence of binding correction. Although this concentration is one order of magnitude lower than that of HSA (40 mg/mL; Ito and Houston, 2005) , bovine serum albumin was shown to affect drug protein binding in plated hepatocytes even at very low concentrations (Chao et al., 2009) .
Integrating either blood binding and/or incubation matrix binding in CL H predictions has been intensively discussed in literature (Obach, 1999; Ito and Houston, 2005; Riley et al., 2005) . In fact there exist several studies reporting comparable or even improved predictions of in vivo CL H disregarding all binding corrections, in particular for basic and neutral compounds (Obach et al., 1997; De Buck et al., 2007; Sohlenius-Sternbeck et al., 2010) . Although we could not correlate prediction accuracy with a particular compound class, these observations are well in line with our results and are further corroborated by an analysis of the Pharmaceutical Research and Manufacturers of America. This report reveals best prediction performance based on in vitro-in vivo correlation by using hepatocyte turnover not corrected for any (protein) binding (Ring et al., 2011) . In view of our experimental results, but also considering the above discussed points, which await deepened investigations, we suggest that UHH cultured under the conditions described in this work are a suitable in vitro model to determine CL int of low CL compounds (AAFE = 2.0; 73% twofold accuracy). Prediction performance was reproducible and comparable to that achieved by other currently used PHH systems under aspects of CL-dependent prediction limitations and accuracy, for example, as published for HepatoPac and the relay method (Di et al., 2012) . The larger underprediction observed for intermediate-cleared drugs in all three donors tested (negative bias on average three-to fourfold for donor 151-03) is consistent with the fourfold underpredictions reported for CL int using PHH . However, a strong correlation between increased protein binding and decreasing prediction accuracy was not observed in our data set (Table 2) .
Our data presented in this study show that prediction performance of CL H was rather dependent on the selected UHH donor (Table 1) , reflecting the interindividual variability in DME. We found an appreciable correlation between the interindividual P450 activity-time profiles and the observed CL int for corresponding reference drugs at selected time points. The metabolic precharacterization of UHH donors was found highly important and contributed further to unraveling observed discrepancies in CL predictions. For example, the .10-fold overestimation of in vivo CL H for diazepam may be attributed to high CYP2C19 activity observed for UHH donor 151-03 (*17/*17 ultrarapid metabolizer phenotype; data not shown) and/or might be triggered by a CYP3A4-mediated autoactivation mechanism (Zuegge et al., 2001 ). The latter is reasonable to assume, as a sufficient depletion of diazepam was also seen for donor 10-03, identified as *2A/*2A poor metabolizer phenotype (data not shown). Although failure of predicting CL H for theophylline and flecainide could be attributed to the relatively low CYP1A2 and CYP2D6 mRNA expression and activities, hepatic CL was successfully predicted for other CYP1A2 and CYP2D6 substrates, for example, riluzole, lidocaine, risperidone, and atomoxetine. Nevertheless, alternative P450 pathways potentially contributing to the overall metabolic turnover or even compensate for impaired P450 activity (Ring et al., 2002) have to be considered and will be included in future investigations.
In summary, second-generation UHH showed a sustained and markedly reproducible functionality of main P450, UGT, and SULT enzymes over a period of 2-3 weeks at levels sufficient for accurate CL prediction of slowly metabolized drugs. We demonstrated the necessity of a thorough metabolic precharacterization of PK-relevant enzymes in UHH donors to account for interindividual variability in DME activity, and to select appropriate assay culture conditions for subsequent CL predictions. Based on our results, we are confident that UHH are of interest for standardized approaches in discovery research, merging advantages of PHH with benefits of hepatic cell lines, that is, ensuring a stable supply of cells with a constant DME phenotype and high batchto-batch consistency. Future studies including expression and functionality of non-P450s and drug transporters over long-term culture will prove the utility of UHH for integrated evaluation of metabolism-and transporter-mediated hepatic CL processes. 3) Tebu-Bio GmbH (Offenbach, Germany)/XenoTech (Lenexa, KS, USA); 4) BioreclamationIVT GmbH (Frankfurt/Main, Germany/Baltimore, MD, USA) ‡) CHRM medium (LifeTechnologies GmbH, Darmstadt, Germany) was used for thawing; Williams´ Medium E (WME) supplemented with 5% fetal bovine serum, 15 mM HEPES (pH 7.4), 6.25 µg/mL insulin, 6.25 µg/mL transferrin, 6.25 ng/mL selenous acid, 5.35 µg/mL linoleic acid, 1.25 mg/mL bovine serum albumin, 1 µM dexamethasone (DEX), 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine for plating (WME complete with 1 µM DEX); WME complete with 0.1 µM DEX for overlay and long-term culturing. * ) Hepatocyte Thawing Kit and Hepatocyte Re-Suspension Medium (XenoTec, Lenexa, KS, USA) were used for plating and XenoTec Hepatocyte Culture Medium for overlay and long-term culturing. † †) WME complete with 0.1 µM DEX instead of XenoTec Hepatocyte Culture Medium was used for overlay and long-term culturing. †) High Viability CryoHepatocyte Recovery Kit (Corning/BD Gentest, Bedford, MA, USA) was used for thawing and plating; WME complete with 0.1 µM DEX for overlay and long-term culturing.
#) InVitro Grow CP Medium (BioreclamationIVT GmbH, Frankfurt, Germany) was used for thawing and plating;
InVitro Grow HI Medium (BioreclamationIVT GmbH) for overlay and log-term culturing. #) Pharmacokinetic parameters for extensive metabolizers, CL estimated from CL/F *) Nonrenal blood clearance estimated from total CL p after oral administration (Piliero et al., 2004) Supplemental 
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